Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2020
Period Ending	Aug '25 Aug 8, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2020
Market Capitalization	452,805	363,457	363,525	185,346	-	-	Upgrade
Market Cap Growth	-13.48%	-0.02%	96.13%	-	-	-	Upgrade
Enterprise Value	362,952	291,198	296,211	114,030	-	-	Upgrade
Last Close Price	20100.00	16200.00	16850.00	8775.00	-	-	Upgrade
PE Ratio	19.65	18.17	-	-	-	-	Upgrade
PS Ratio	15.25	13.21	-	926.73	-	-	Upgrade
PB Ratio	4.90	4.00	6.30	2.68	-	-	Upgrade
P/TBV Ratio	4.93	4.02	6.33	2.69	-	-	Upgrade
P/FCF Ratio	20.25	16.89	-	-	-	-	Upgrade
P/OCF Ratio	20.00	16.55	-	-	-	-	Upgrade
EV/Sales Ratio	12.23	10.58	-	570.15	-	-	Upgrade
EV/EBITDA Ratio	18.17	16.57	-	-	-	-	Upgrade
EV/EBIT Ratio	18.83	17.26	-	-	-	-	Upgrade
EV/FCF Ratio	16.23	13.54	-	-	-	-	Upgrade
Debt / Equity Ratio	0.04	0.03	0.10	0.01	0.01	-0.38	Upgrade
Debt / EBITDA Ratio	0.16	0.18	-	-	0.07	-	Upgrade
Debt / FCF Ratio	0.14	0.14	-	-	0.14	-	Upgrade
Asset Turnover	0.33	0.31	-	0.00	0.58	-	Upgrade
Quick Ratio	11.46	11.33	2.95	38.63	14.54	0.86	Upgrade
Current Ratio	11.52	11.39	3.07	38.81	14.68	0.90	Upgrade
Return on Equity (ROE)	30.45%	26.90%	-22.27%	-14.18%	-186.52%	-	Upgrade
Return on Assets (ROA)	13.44%	11.76%	-11.10%	-10.83%	6.88%	-41.42%	Upgrade
Return on Capital (ROIC)	15.25%	13.37%	-12.57%	-11.29%	9.73%	-2566.28%	Upgrade
Return on Capital Employed (ROCE)	20.90%	18.50%	-	-	7.80%	-	Upgrade
Earnings Yield	5.00%	5.50%	-3.89%	-4.83%	-	-	Upgrade
FCF Yield	4.94%	5.92%	-2.91%	-3.67%	-	-	Upgrade
Buyback Yield / Dilution	8.17%	-2.66%	-9.11%	-134.61%	-139.04%	-400.04%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.